T Piticchio1, R Le Moli1, D Tumino1, F Frasca2. 1. Endocrinology Section, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95122, Catania, Italy. 2. Endocrinology Section, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95122, Catania, Italy. f.frasca@unict.it.
Abstract
BACKGROUND: A new harmful respiratory disease, called COVID-19 emerged in China in December 2019 due to the infection of a novel coronavirus, called SARS-Coronavirus 2 (SARS-CoV-2), which belongs to the betacoronavirus genus, including SARS-CoV-1 and MERS-CoV. SARS-CoV-2 shares almost 80% of the genome with SARS-CoV-1 and 50% with MERS-CoV. Moreover, SARS-CoV-2 proteins share a high degree of homology (approximately 95%) with SARS-CoV-1 proteins. Hence, the mechanisms of SARS-Cov-1 and SARS-Cov-2 infection are similar and occur via binding to ACE2 protein, which is widely distributed in the human body, with a predominant expression in endocrine tissues including testis, thyroid, adrenal and pituitary. PURPOSE: On the basis of expression pattern of the ACE2 protein among different tissues, similarity between SARS-Cov-1 and SARS-Cov-2 and the pathophysiology of COVID-19 disease, we aimed at discussing, after almost one-year pandemic, about the relationships between COVID-19 infection and the endocrine system. First, we discussed the potential effect of hormones on the susceptibility to COVID-19 infection; second, we examined the evidences regarding the effect of COVID-19 on the endocrine system. When data were available, a comparative discussion between SARS and COVID-19 effects was also performed. METHODS: A comprehensive literature search within Pubmed was performed. This review has been conducted according to the PRISMA statements. RESULTS: Among 450, 100 articles were selected. Tissue and vascular damages have been shown on thyroid, adrenal, testis and pituitary glands, with multiple alterations of endocrine function. CONCLUSION: Hormones may affect patient susceptibility to COVID-19 infection but evidences regarding therapeutic implication of these findings are still missing. SARS and COVID-19 may affect endocrine glands and their dense vascularization, impairing endocrine system function. A possible damage of endocrine system in COVID-19 patients should be investigated in both COVID-19 acute phase and recovery to identify both early and late endocrine complications that may be important for patient's prognosis and well-being after COVID-19 infection.
BACKGROUND: A new harmful respiratory disease, called COVID-19 emerged in China in December 2019 due to the infection of a novel coronavirus, called SARS-Coronavirus 2 (SARS-CoV-2), which belongs to the betacoronavirus genus, including SARS-CoV-1 and MERS-CoV. SARS-CoV-2 shares almost 80% of the genome with SARS-CoV-1 and 50% with MERS-CoV. Moreover, SARS-CoV-2 proteins share a high degree of homology (approximately 95%) with SARS-CoV-1 proteins. Hence, the mechanisms of SARS-Cov-1 and SARS-Cov-2 infection are similar and occur via binding to ACE2 protein, which is widely distributed in the human body, with a predominant expression in endocrine tissues including testis, thyroid, adrenal and pituitary. PURPOSE: On the basis of expression pattern of the ACE2 protein among different tissues, similarity between SARS-Cov-1 and SARS-Cov-2 and the pathophysiology of COVID-19 disease, we aimed at discussing, after almost one-year pandemic, about the relationships between COVID-19infection and the endocrine system. First, we discussed the potential effect of hormones on the susceptibility to COVID-19infection; second, we examined the evidences regarding the effect of COVID-19 on the endocrine system. When data were available, a comparative discussion between SARS and COVID-19 effects was also performed. METHODS: A comprehensive literature search within Pubmed was performed. This review has been conducted according to the PRISMA statements. RESULTS: Among 450, 100 articles were selected. Tissue and vascular damages have been shown on thyroid, adrenal, testis and pituitary glands, with multiple alterations of endocrine function. CONCLUSION: Hormones may affect patient susceptibility to COVID-19infection but evidences regarding therapeutic implication of these findings are still missing. SARS and COVID-19 may affect endocrine glands and their dense vascularization, impairing endocrine system function. A possible damage of endocrine system in COVID-19patients should be investigated in both COVID-19 acute phase and recovery to identify both early and late endocrine complications that may be important for patient's prognosis and well-being after COVID-19infection.
Authors: Xiaolei Cai; Aleksander Prominski; Yiliang Lin; Nicholas Ankenbruck; Jillian Rosenberg; Min Chen; Jiuyun Shi; Eugene B Chang; Pablo Penaloza-MacMaster; Bozhi Tian; Jun Huang Journal: bioRxiv Date: 2020-11-30
Authors: J K Yang; Y Feng; M Y Yuan; S Y Yuan; H J Fu; B Y Wu; G Z Sun; G R Yang; X L Zhang; L Wang; X Xu; X P Xu; J C N Chan Journal: Diabet Med Date: 2006-06 Impact factor: 4.359
Authors: Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann Journal: Cell Date: 2020-03-05 Impact factor: 41.582
Authors: Mojca Jensterle; Rok Herman; Andrej Janež; Wael Al Mahmeed; Khalid Al-Rasadi; Kamila Al-Alawi; Maciej Banach; Yajnavalka Banerjee; Antonio Ceriello; Mustafa Cesur; Francesco Cosentino; Massimo Galia; Su-Yen Goh; Sanjay Kalra; Peter Kempler; Nader Lessan; Paulo Lotufo; Nikolaos Papanas; Ali A Rizvi; Raul D Santos; Anca P Stoian; Peter P Toth; Vijay Viswanathan; Manfredi Rizzo Journal: Int J Mol Sci Date: 2022-06-30 Impact factor: 6.208
Authors: G Ceccarini; D Gilio; S Magno; C Pelosini; M Leverone; C Miceli; A Barison; I Fabiani; M Emdin; F Santini Journal: J Endocrinol Invest Date: 2022-04-06 Impact factor: 5.467
Authors: G Biganzoli; D Dilillo; E Biganzoli; G Zuccotti; V Calcaterra; S Mannarino; L Fiori; G Pelizzo; E Zoia; V Fabiano; P Carlucci; A Camporesi; C Corti; G Mercurio; F Izzo Journal: J Endocrinol Invest Date: 2021-07-26 Impact factor: 4.256